Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Irodanoprost by Mesentech for Duchenne Muscular Dystrophy: Likelihood of Approval
Irodanoprost is under clinical development by Mesentech and currently in Phase I for Duchenne Muscular Dystrophy. According to GlobalData, Phase...